oral antibiotic
FDA Approves Iterum’s Orlynvah for Uncomplicated UTIs, Offering New Hope for Patients with Limited Treatment Options
Iterum Therapeutics, Orlynvah, FDA approval, uncomplicated urinary tract infections (uUTIs), oral antibiotic, sulopenem, antimicrobial resistance